Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 551 - 575 of 14814 in total
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in...
Approved
Matched Description: … It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies ... [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 ... [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Approved
Illicit
Matched Description: … A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Approved
Investigational
Matched Categories: … ethambutol and isoniazid ... rifampicin and isoniazid ... streptomycin and isoniazid ... thioacetazone and isoniazid ... rifampicin, ethambutol and isoniazid …
A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]
Approved
Investigational
Matched Description: … A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. ... It also serves as an antioxidant in fats and oils. [PubChem] ... The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Approved
Investigational
Matched Description: … It was approved in Europe in February 2015, and in the United States on March 21, 2017. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates …
Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as DB13999 . It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It...
Approved
Investigational
Matched Description: … Patients with this disorder are more susceptible to recurrent bleeding episodes and excessive bleeding ... Other drug products with similar structure and function to Efmoroctocog alfa include [DB13999], which ... is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits. …
Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections.[L6856,L6859,L6862] Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts...
Approved
Vet approved
Matched Description: … to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and
Etilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors. It has been used as a vasoconstrictor agent.
Approved
Withdrawn
Matched Description: … Etilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors …
Matched Categories: … Adrenergic and Dopaminergic Agents …
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. ... the growth of normal and malignant prostatic tissue. ... Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It...
Approved
Vet approved
Matched Description: … This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection ... It is slowly absorbed and hydrolyzed to benzylpenicillin. ... salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class...
Approved
Investigational
Matched Description: … Sulfonylureas are associated with weight gain, though less so than insulin. ... increase the number and sensitivity of insulin receptors. ... Renal and hepatic dysfunction may increase the risk of hypoglycemia. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
A benzodiazepine derivative used mainly as a hypnotic.
Approved
Illicit
Investigational
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepines and benzodiazepine derivatives …
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … are therefore safer for use in patients with contraindications to standard therapy. ... [L38814] The current standard of migraine therapy involves abortive treatment with "triptans", such ... as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular …
Rezafungin is an echinocandin antifungal drug.[A258393,L45633] Unlike other echinocandins such as caspofungin and micafungin, rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high plasma exposure. Rezafungin has a half-life higher than 130 hours and can be administered once a week...
Approved
Investigational
Matched Description: … invasive candidiasis in adults with limited or no alternative treatment options. ... _Candida tropicalis_, as well as other _Candida_ and _Aspergillus_ spp. ... Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996....
Approved
Vet approved
Matched Description: … [L42340] It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition ... The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients ... Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. …
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Approved
Matched Description: … Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 ... peripheral origin, and as an adjuvant in the therapy of epilepsy. ... effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and
Matched Categories: … Calcium-Regulating Hormones and Agents …
Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon.[A262102,A262107] Indeed, oncogenic activation,...
Approved
Investigational
Matched Description: … Therefore, the advent of fruquintinib, a new generation of VEGFR inhibitors with a high kinome selectivity ... fruquintinib was approved by the FDA under the brand name Fruzaqla for the treatment of adult patients with ... chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid...
Approved
Matched Description: … of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. ... third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and ... [A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia …
Matched Categories: … Drugs Affecting Bone Structure and Mineralization ... zoledronic acid, calcium and colecalciferol, sequential …
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1....
Approved
Investigational
Matched Description: … [L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region ... variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse...
Approved
Illicit
Investigational
Matched Description: … [L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ... ketoconazole and itraconazole. ... [A18125] Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepines and benzodiazepine derivatives …
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation...
Approved
Investigational
Matched Description: … [A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole ... [clotrimazole], due to its broad spectrum and good absorption. ... agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. …
Matched Categories: … Sex Hormones and Insulins ... Imidazole and Triazole Derivatives ... Gynecological Antiinfectives and Antiseptics ... Metabolic Side Effects of Drugs and Substances …
Propiolactone is a lactone compound with a four-membered ring. It is a colorless liquid with a pungent slightly sweet odor. Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical instruments, and enzymes. It has been used against bacteria, fungi, and virus. It is currently...
Approved
Withdrawn
Matched Description: … It has been used against bacteria, fungi, and virus. ... Propiolactone is a lactone compound with a four-membered ring. ... It is a colorless liquid with a pungent slightly sweet odor. …
Halazepam is a benzodiazepine derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by Schering, its manufacturer, in 2009.[L6226, L6229]
Approved
Illicit
Withdrawn
Matched Description: … [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti.
Approved
Matched Description: … with ocular surgery. ... Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Nonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). Nonacog...
Approved
Investigational
Matched Description: … It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) ... Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor ... [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Displaying drugs 551 - 575 of 14814 in total